Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMLW57T)

Drug Name
Teniposide Drug Info
Synonyms
PTG; Teniposido; Teniposidum; Vehem; Vumon; Demethyl Epipodophyllotoxin Thenylidine Glucoside; VM 26; Teniposido [INN-Spanish]; Teniposidum [INN-Latin]; VM-26; Vee M-26; Veham-Sandoz; Vumon (TN); Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; VM-26 (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
452548
ChEBI ID
CHEMBL452231
CAS Number
CAS 29767-20-2
TTD Drug ID
D01DBQ
VARIDT Drug ID
DR00021
INTEDE Drug ID
DR1550

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
p53 signaling pathway 2.56 0.00e+0 63/73 (86.3%) SESN1;CDKN1A;DDB2;...
Epstein-Barr virus infection 2.18 0.00e+0 189/202 (93.56%) CDKN1A;DDB2;GADD45A;...
Graft-versus-host disease 2.13 0.00e+0 32/42 (76.19%) FAS;HLA-B;HLA-A;...
Herpes simplex virus 1 infection 2.12 0.00e+0 165/498 (33.13%) FAS;NFKBIA;TAP1;...
Allograft rejection 2.11 0.00e+0 32/38 (84.21%) FAS;HLA-B;HLA-A;...
Oxidative phosphorylation 2.02 0.00e+0 93/133 (69.92%) SDHD;NDUFB1;ATP5PF;...
Non-alcoholic fatty liver disease 2.00 1.52e-3 126/155 (81.29%) FAS;JUN;CXCL8;...
Viral protein interaction with cytokine and cytokine re... 1.97 1.33e-3 84/100 (84%) TNFRSF10B;CCL2;CXCL8;...
TNF signaling pathway 1.96 1.18e-3 103/112 (91.96%) FAS;NFKBIA;JAG1;...
Parkinson disease 1.96 1.07e-3 176/249 (70.68%) PPIF;SLC25A4;SDHD;...
Type I diabetes mellitus 1.95 1.94e-3 38/43 (88.37%) FAS;HLA-B;HLA-A;...
Small cell lung cancer 1.93 2.66e-3 90/92 (97.83%) CDKN1A;DDB2;GADD45A;...
Cytosolic DNA-sensing pathway 1.92 2.46e-3 52/63 (82.54%) NFKBIA;CXCL10;CCL5;...
Influenza A 1.91 3.81e-3 156/172 (90.7%) FAS;NFKBIA;TNFRSF10B;...
RIG-I-like receptor signaling pathway 1.91 3.55e-3 64/70 (91.43%) NFKBIA;CXCL8;CXCL10;...
NOD-like receptor signaling pathway 1.90 4.00e-3 145/181 (80.11%) NFKBIA;CCL2;JUN;...
Autoimmune thyroid disease 1.89 3.76e-3 46/53 (86.79%) FAS;HLA-B;HLA-A;...
Chronic myeloid leukemia 1.88 3.55e-3 72/76 (94.74%) CDKN1A;DDB2;GADD45A;...
Basal cell carcinoma 1.87 5.05e-3 41/63 (65.08%) CDKN1A;DDB2;GADD45A;...
NF-kappa B signaling pathway 1.86 4.80e-3 90/104 (86.54%) GADD45A;NFKBIA;RELB;...
Legionellosis 1.84 6.09e-3 51/57 (89.47%) NFKBIA;CXCL8;CASP8;...
Measles 1.83 5.81e-3 133/139 (95.68%) FAS;NFKBIA;JUN;...
C-type lectin receptor signaling pathway 1.83 6.49e-3 93/104 (89.42%) NFKBIA;RELB;JUN;...
Apoptosis 1.81 6.66e-3 126/168 (75%) GADD45A;FAS;NFKBIA;...
Proteasome 1.81 6.39e-3 44/46 (95.65%) PSMB8;PSMB5;PSMB9;...
Toxoplasmosis 1.77 8.61e-3 103/112 (91.96%) NFKBIA;PPIF;SOCS1;...
Necroptosis 1.75 1.18e-2 113/159 (71.07%) FAS;TNFRSF10B;TNFSF10;...
IL-17 signaling pathway 1.75 1.14e-2 84/94 (89.36%) NFKBIA;FOSL1;CCL2;...
Mannose type O-glycan biosynthesis 1.74 1.21e-2 14/23 (60.87%) POMGNT1;RXYLT1;B4GAT1
Cytokine-cytokine receptor interaction 1.73 1.21e-2 246/295 (83.39%) FAS;TNFRSF10B;CCL2;...
Regulation of actin cytoskeleton -1.69 4.83e-2 185/218 (84.86%) ARHGEF6;ITGB6;GNA12;...
Complement and coagulation cascades -1.70 4.49e-2 76/85 (89.41%) C2;F12;C5AR1;...
Melanogenesis -1.71 4.56e-2 74/101 (73.27%) FZD10;MAPK3;ADCY3;...
Cortisol synthesis and secretion -1.74 3.17e-2 58/65 (89.23%) AGTR1;ADCY3;CACNA1D;...
Glutamatergic synapse -1.77 2.73e-2 97/114 (85.09%) PPP3R1;GNG11;PRKACB;...
Morphine addiction -1.82 1.76e-2 80/91 (87.91%) ARRB1;GABRB3;DRD1;...
Mineral absorption -1.83 1.74e-2 48/60 (80%) ATP1A3;STEAP1;SLC26A3;...
Cell cycle -1.87 5.70e-3 110/124 (88.71%) ORC5;PKMYT1;BUB3;...
Adherens junction -1.94 2.37e-3 63/71 (88.73%) AFDN;LMO7;IQGAP1;...
Oocyte meiosis -2.02 0.00e+0 90/129 (69.77%) ANAPC1;MAPK1;PPP2R5A;...
Steroid biosynthesis -2.07 0.00e+0 19/20 (95%) LSS;DHCR7;SQLE;...
Progesterone-mediated oocyte maturation -2.23 0.00e+0 75/100 (75%) ANAPC10;PIK3CB;HSP90AB1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 1.25uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.002uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 1.25uM 6H
HT-29 CVCL_0320 Homo sapiens 1.25uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 1.25uM 6H
MDST8 CVCL_1400 Homo sapiens 1.25uM 6H
NCI-H508 CVCL_1561 Homo sapiens 1.25uM 6H
SNU-1040 CVCL_5001 Homo sapiens 1.25uM 6H
SNU-C4 CVCL_5008 Homo sapiens 1.25uM 6H
SNU-C5 CVCL_5009 Homo sapiens 1.25uM 6H
SW480 CVCL_0546 Homo sapiens 1.25uM 6H
SW620 CVCL_0547 Homo sapiens 1.25uM 6H
SW948 CVCL_0550 Homo sapiens 1.25uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 1.25uM 6H
HT115 CVCL_1294 Homo sapiens 1.25uM 6H
RKO CVCL_0504 Homo sapiens 1.25uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.25uM 6H
SNG-M CVCL_1707 Homo sapiens 1.25uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 1.25uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 1.25uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 1.25uM - 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.002uM - 10uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 1.25uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 1.25uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 1.25uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 1.25uM 6H
T3M-10 CVCL_1729 Homo sapiens 1.25uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 1.25uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 1.25uM 6H
HCC515 CVCL_5134 Homo sapiens 1.25uM - 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 1.25uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 1.25uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 1.25uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 1.25uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 1.25uM 6H
OV7 CVCL_1623 Homo sapiens 1.25uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 1.25uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 1.25uM 6H
RMUG-S CVCL_1666 Homo sapiens 1.25uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 1.25uM 6H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 1.25uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 1.25uM 6H
PL-21 CVCL_2161 Homo sapiens 1.25uM 6H
SKM-1 CVCL_0010 Homo sapiens 1.25uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 1.25uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 1.25uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 1.25uM - 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 1.25uM - 10uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 1.25uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 1.25uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 1.25uM 6H